BioInvest In The News

The Life Sciences Report (5-9-13)
The Life Sciences Report (1-31-13)
The Stock Advisors (1-17-13)
Dick Davis Investment Digest (1-09-13)
Forbes (12-8-12)
The Stock Advisors (11-27-12)
Company Updates
Incyte Update (5-16-13)

Incyte Update (5-16-13)

ASCO ABSTRACTS CONFIRM BULLISH STANCE ON PCYC AND INCY –  Keeping it simple, two key abstracts were released online last night for the upcoming ASCO conference (5/31-6/4, Chicago) support our favorable thesis on INCY and PCYC (see PCYC Update). Incyte’s INCY’s Jakafi improves bone marrow fibrosis – Abstract #7030 is a study evaluating BM fibrosis [...]

Novavax Update (4-25-13)

Novavax Update (4-25-13)

NovaVax – Why VLPs are VIPs. The key to the NVAX vaccine platform technology is the use of virus-like particles (VLPs) to safely deliver key immune-identifying proteins to the body.  Importantly, proof of concept is in place as VLPs are recombinant particles similar to currently marketed vaccines.  Merck’s Recombivax HB and GSK’s Engerix B are recombinant [...]

Pharmacyclics Update (4-24-13)

Pharmacyclics Update (4-24-13)

Pharmacyclics (4/24/13) – Completes Enrollment of RESONATE and SPARK Well Ahead of Schedule – Continue to Expect Ibrutib on Market This Year, Ahead of All Expectations. Completion of both trials, RESONATE (CLL) and SPARK (MCL), approximately 6-9 months ahead of forecasts supports our belief that ibrutinib is on track to be approved in the U.S. in [...]